Industry Overview - The global anti-obesity drug market is projected to generate $12.8 billion in sales this year, with expectations to grow to $104.9 billion by 2035 [1] - Demand for effective weight management drugs is significant, indicating a robust market potential [1] Company Analysis: Novo Nordisk and Eli Lilly - Novo Nordisk currently markets the top-selling GLP-1 drug but is losing market share to Eli Lilly's tirzepatide, marketed as Zepbound [2] - Eli Lilly's Zepbound is experiencing soaring sales, while Viking Therapeutics is developing a potential competitor, VK2735, which may outperform Zepbound based on early clinical trial data [3][4] Viking Therapeutics - Viking Therapeutics' VK2735 showed a 13.1% average weight loss in a phase 2 trial after 13 weeks, suggesting potential for better performance compared to Zepbound's 17.8% reduction after 72 weeks [5][6] - Despite positive phase 2 results, Viking Therapeutics has not yet initiated a phase 3 trial for VK2735, leading to a 70% drop in its stock price from last year's peak [8] - The company also reported successful phase 2 results for VK2809, but has not started the necessary phase 3 trial [9] Eli Lilly's Growth - Eli Lilly's fourth-quarter revenue, including sales from both tirzepatide brands, increased by 45% year over year to $13.5 billion, with significant growth in other drug categories as well [10][11] - The company expects total sales to grow by 32% in 2025, supported by multiple recently launched therapies [12] - Eli Lilly's retatrutide, an experimental triple hormone receptor agonist, demonstrated a weight reduction of up to 24.2% after 48 weeks, with ongoing phase 3 trials expected to yield results by the end of 2025 [13] Investment Outlook - Viking Therapeutics is considered a high-risk investment due to delays in advancing its pipeline, making it less attractive for investors [14] - Eli Lilly, despite a high valuation, is positioned for faster growth and is likely to provide positive long-term returns, making it a more favorable investment option [15]

Last year, Viking Therapeutics (VKTX 1.83%), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical trial results. The company's shares soared in late February 2024, but, unfortunately, they have been southbound since then. Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain unashamedly bullish on the company.Viking's average price target of $99.29 (according to analysts tracked by Yahoo! Finance) implies an up ...

Viking Therapeutics (VKTX -0.07%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.While the optimism surrounding the drug made Viking's stock a hot buy early last year, things have drastically cooled over the past six months during which it has plummeted more than 50%. As a result, the stock is now down 65% fr ...

Group 1 - The article discusses the potential for investing in undervalued stocks that are mispriced by the market as the end of Q1 approaches [1] - It suggests that investors may consider joining a platform called Out Fox The Street for insights on positioning in these stocks [1] Group 2 - There is a mention of a potential beneficial long position in VKTX that may be initiated within the next 72 hours [2] - The article emphasizes that the opinions expressed are those of the author and not influenced by any compensation from companies mentioned [2] Group 3 - The information provided is intended for informational purposes only and does not constitute a solicitation to buy or sell securities [3] - It highlights the importance of conducting personal research or consulting a financial advisor before making investment decisions [3] Group 4 - The article notes that past performance is not indicative of future results and that no specific investment recommendations are being made [4] - It clarifies that the views expressed may not represent those of Seeking Alpha as a whole and that the analysts involved may not be licensed or certified [4]

Shares of Viking Therapeutics (VKTX) gained more than 11% on Wednesday after the company announced that it had signed a broad multi-year manufacturing agreement with CordenPharma for both the oral and subcutaneous (SC) formulations of its obesity drug.Viking Therapeutics is one of the few biotech stocks that has shown immense potential in the obesity space. It is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist, in different clinical studies as oral and SC versions for treatin ...

Viking Therapeutics (VKTX) signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC) formulations of its obesity drug VK2735.Per the terms, Viking has secured dedicated manufacturing capacity to support the large-scale production of VK2735. The deal includes an annual supply commitment for multiple metric tons of the active pharmaceutical ingredient (API) behind VK2735, along with fill/finish cap ...

Group 1 - The Growth Stock Forum focuses on identifying attractive risk/reward situations in growth stocks, particularly in the biotech sector [1][2] - The forum features a model portfolio of 15-20 stocks that is updated regularly, along with a top picks list of up to 10 stocks expected to perform well in the current calendar year [2] - The forum provides trading ideas targeting both short-term and medium-term market movements, along with community dialogue for questions [2]

Core Insights - JR Research is recognized as a top analyst in technology, software, and internet sectors, focusing on growth and GARP strategies [1] - The investment approach emphasizes identifying attractive risk/reward opportunities with robust price action to generate alpha above the S&P 500 [1][2] - The investment group Ultimate Growth Investing specializes in high-potential opportunities across various sectors with a focus on strong growth potential and contrarian plays [3] Investment Strategy - The strategy combines sharp price action analysis with fundamentals investing, avoiding overhyped stocks while targeting battered stocks with recovery potential [2] - The investment outlook is typically 18 to 24 months for the thesis to materialize, aiming for robust fundamentals and attractive valuations [3] Target Audience - The group is designed for investors looking to capitalize on growth stocks with strong fundamentals, buying momentum, and turnaround plays [3]

CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation. BASEL, Switzerland, March 11, 2025 /PRNewswire/ -- CordenPharma, a leading ...

 Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical IngredientSecures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe SupplyProvides Annual Capacity of Over 1 Billion Oral TabletsViking to Make Prepayments Totaling $150 Million Between 2025-2028SAN DIEGO, March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company ...